private digital health companies obesity management glp-1 Virtual startups: Pill mills or the future of care? A whole person view of

Mechanism of action of the bile acid receptor TGR5 in obesity

MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies

If youre losing weight quickly and arent strength training, your body has fewer reasons to hold onto muscle

Similarly, any existing lesion that changes size, shape, or color should be evaluated promptly

In follicles where melanocytes are still present but inactive, certain compounds can reawaken pigment production

Compounded Medication Notice: SkinnyRx's primary medication offerings are compounded prescription products prepared by licensed 503A pharmacies based on individual prescriptions